Stock Price
159.43
Daily Change
-5.48 -3.32%
Monthly
-0.18%
Yearly
99.21%
Q1 Forecast
159.80

Insmed reported $468.87M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
DBV Technologies USD 49.48M 60K Sep/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Heron Therapeutics USD 89.71M 168.89M Sep/2025
Insmed USD 468.87M 51.66M Dec/2025
Novartis USD 32B 286M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025